Repare Therapeutics (RPTX) said late Thursday it is refocusing its resources on advancing phase 1 clinical programs for RP-1664 in solid tumors and RP-3467 in certain types of cancer.
The company also intends to seek partnerships for lunresertib and camonsertib before starting the next trials.
The strategic realignment, combined with cost and headcount reductions, is expected to extend the company's funds of $153 million until mid-2027, it added.
Repare said it will discontinue other lunresertib and camonsertib studies unless a suitable development partner is found.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.